Skip to main content
Staidson (Beijing) Biopharmaceuticals Co.,Ltd. logo

Staidson (Beijing) Biopharmaceuticals Co.,Ltd. — Investor Relations & Filings

Ticker · 300204 ISIN · CNE100001237 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,167 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300204

About Staidson (Beijing) Biopharmaceuticals Co.,Ltd.

https://www.staidson.com

Staidson (Beijing) Biopharmaceuticals Co., Ltd. specializes in the research, development, and commercialization of innovative therapeutic biologicals. The company's primary focus areas include neurology, hematology, and infectious diseases. Its core product portfolio features Mouse Nerve Growth Factor for injection, utilized in the treatment of nerve injuries, and Parnaparin Sodium, a low molecular weight heparin indicated for thrombotic disorders. Staidson's research and development pipeline includes various monoclonal antibodies and recombinant proteins, such as STSA-1002 and STSA-1005, which target systemic inflammatory responses and acute respiratory distress. The organization maintains integrated capabilities spanning drug discovery, clinical development, and large-scale manufacturing to deliver specialized medical treatments.

Recent filings

Filing Released Lang Actions
北京市康达律师事务所关于舒泰神2025年年度股东会法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter issued by Kangda Law Firm regarding the convening, procedures, and voting results of the company’s 2025 annual shareholders’ meeting. It does not itself present financial data or constitute an annual/interim report; rather, it is an external legal certification/attestation of the AGM process. Under the “Certification Rule,” such officer/legal adviser attestations are classified as general regulatory filings. Therefore, the appropriate category is Regulatory Filings (RNS).
2026-05-19 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 89% confidence The document is titled “2025年年度股东会决议公告” and lists each AGM proposal with the detailed vote counts (for/against/abstain) for both all shareholders and small investors. It is clearly an announcement of AGM voting results, matching Declaration of Voting Results & Voting Rights Announcements.
2026-05-19 Chinese
舒泰神（北京）生物制药股份有限公司2025年度向特定对象发行股票募集说明书（注册稿）
Share Issue/Capital Change Classification · 90% confidence The document is a detailed Chinese prospectus (募集说明书) for a 2025 private placement of A‐shares to specific investors by 舒泰神（北京）生物制药股份有限公司, including offering terms, risk factors, use of proceeds, and share issuance plan. It is not an annual report or interim report, but a full regulatory offering document focused on raising equity capital. This aligns with the Share Issue/Capital Change category.
2026-05-18 Chinese
关于向特定对象发行股票申请获得中国证监会同意注册批复的公告
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement that the company has received CSRC approval for a targeted share issuance, detailing the registration approval and next steps. This is clearly an announcement of a new share issue to specific investors, matching the “Share Issue/Capital Change” category (SHA).
2026-05-18 Chinese
关于公司药品生产许可证变更的公告
Regulatory Filings Classification · 85% confidence The document is a public announcement by the company regarding the change/extension of its drug production license issued by the Beijing Municipal Drug Supervision Bureau. It provides regulatory compliance details (license number, new scope, effective period, production sites) and risk disclosures. It is not a financial report, earnings release, management change, or other specific filing category. It is a general compliance/regulatory announcement, which fits the fallback “Regulatory Filings” category.
2026-05-15 Chinese
关于召开2025年年度股东会的提示性公告
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a formal notice (‘提示性公告’) convening the 2025 Annual General Meeting, detailing date, venue, agenda items, proxy form and voting procedures. It is clearly a meeting‐notice and proxy solicitation package rather than the report itself. This fits the Proxy Solicitation & Information Statement category (PSI).
2026-05-14 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.